Related Experiment Video
Updated: May 9, 2026

Breath Collection from Children for Disease Biomarker Discovery
Published on: February 14, 2019
Exhaled breath volatiles for asthma diagnosis: discovery and validation in untreated but symptomatic patients
Agnieszka Turlo1,2, Waqar Ahmed1,2, Ran Wang1
1Division of Immunology, Immunity to Infection & Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK.
Abstract:
Approximately 30% of people with a clinical diagnosis of asthma do not have the condition. Exhaled volatile organic compounds (VOCs) hold promise for non-invasive asthma testing; however, discovery of breath biomarkers is confounded by high biological and technical variability. We collected repeated breath samples from symptomatic patients being tested for asthma before starting treatment. Background samples were collected immediately before patient sampling to characterize VOCs present in the preconditioned inspired airstream. VOCs were measured by thermal desorption-gas chromatography-mass spectrometry. Data from two cohorts (n = 62, 53) were processed independently and used as training and validation datasets. VOCs were classified as breath-enriched or ambiguous based on comparison between breath and background abundance using Wilcoxon test and log fold change. Associations between breath VOCs and diagnosis were tested with univariate mixed-effect models and multivariate classification models. Here we show that background has significant effect on breath VOC abundance in 60% of identified compounds. Breath VOCs show high inter-session and inter-patient variability, reflected by increase in multivariate model classification error in cross-validation (37%) and validation (52%) cohorts. Among VOCs positively associated with asthma, 30% are breath-enriched. Ethyl butanoate, 2-methylfuran and 3-methylpentane show consistent discrimination performance across the cohorts. When used in conjunction with clinical tests, these breath VOCs have comparable contribution to asthma prediction accuracy to established clinical diagnostics such as fractional exhaled nitric oxide. Measuring exhaled VOCs could add value to diagnosis of asthma based on routine clinical tests. However, developing measures to limit technical variation in breath analysis is needed to support discovery and clinical translation of such biomarkers.
More Related Videos
09:19Capturing Actively Produced Microbial Volatile Organic Compounds from Human-Associated Samples with Vacuum-Assisted Sorbent Extraction
Published on: June 1, 2022
08:23Real-time Breath Analysis by Using Secondary Nanoelectrospray Ionization Coupled to High Resolution Mass Spectrometry
Published on: March 9, 2018
Related Concept Videos
Asthma III: Clinical Manifestations
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Asthma I: Introduction
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Asthma-I: Introduction